Literature DB >> 22304562

Differential expression of folate receptor-alpha, sodium-dependent multivitamin transporter, and amino acid transporter (B (0, +)) in human retinoblastoma (Y-79) and retinal pigment epithelial (ARPE-19) cell lines.

Jwala Jwala1, Ramya Krishna Vadlapatla, Aswani Dutt Vadlapudi, Sai Hanuman Sagar Boddu, Dhananjay Pal, Ashim K Mitra.   

Abstract

PURPOSE: The overall objective of this study was to investigate the differential expression of folate receptor-alpha (FR-α), sodium-dependent multivitamin transporter (SMVT), and amino acid transporter [B ((0, +))] in retinoblastoma (Y-79) and retinal pigment epithelial (ARPE-19) cells.
METHODS: Polymerase chain reaction (PCR) analysis was performed to confirm the existence of FR-α, SMVT, and B ((0, +)) in Y-79 and ARPE-19 cell lines. Quantitative real-time PCR was also performed to determine the relative expression of FR-α, SMVT, and B ((0, +)) at mRNA level in these cell lines. Quantitative uptake of [(3)H] Folic acid, [(3)H] Biotin, and [(14)C] Arginine was studied in Y-79 and ARPE-19 cells. Further, saturation kinetics of [(3)H] Folic acid, [(3)H] Biotin, and [(14)C] Arginine was performed in the presence of various concentrations of respective cold substrates to determine the kinetic parameters (K(m) and V(max)) in Y-79 and ARPE-19 cells.
RESULTS: PCR analysis had confirmed the existence of FR-α, SMVT, and B ((0, +)) in Y-79 and ARPE-19 cells. Quantitative real-time PCR analysis had shown significantly higher expression of FR-α, SMVT, and B ((0, +)) mRNA levels in Y-79 cells compared with ARPE-19 cells. Quantitative uptake of [(3)H] Folic acid, [(3)H] Biotin, and [(14)C] Arginine was found to be significantly higher in Y-79 cells relative to ARPE-19 cells. [(3)H] Folic acid uptake process followed saturation kinetics with apparent K(m) of 8.29 nM and V(max) of 393.47 fmol/min/mg protein in Y-79 cells and K(m) of 80.55 nM and V(max) of 491.86 fmol/min/mg protein in ARPE-19 cells. [(3)H] Biotin uptake process also displayed saturation kinetics with K(m) of 8.53 μM and V(max) of 14.12 pmol/min/mg protein in Y-79 cells and K(m) of 138.25 μM and V(max) of 38.85 pmol/min/mg protein in ARPE-19 cells. [(14)C] Arginine uptake process followed saturation kinetics with K(m) of 16.77 μM and V(max) of 348.27 pmol/min/mg protein in Y-79 cells and K(m) of 52.03 μM and V(max) of 379.21 pmol/min/mg protein in ARPE-19 cells.
CONCLUSIONS: This work demonstrated for the first time the higher expression and affinity of FR-α, SMVT, and B ((0, +)) mRNA levels in retinoblastoma (Y-79) cells compared with retinal pigment epithelial (ARPE-19) cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22304562      PMCID: PMC3361182          DOI: 10.1089/jop.2011.0155

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  32 in total

Review 1.  Prodrug based optimal drug delivery via membrane transporter/receptor.

Authors:  C Yang; G S Tirucherai; A K Mitra
Journal:  Expert Opin Biol Ther       Date:  2001-03       Impact factor: 4.388

2.  Neurotrophic activity of interphotoreceptor matrix on human Y79 retinoblastoma cells.

Authors:  J Tombran-Tink; A Li; M A Johnson; L V Johnson; G J Chader
Journal:  J Comp Neurol       Date:  1992-03-08       Impact factor: 3.215

3.  Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies.

Authors:  N Kartner; D Evernden-Porelle; G Bradley; V Ling
Journal:  Nature       Date:  1985 Aug 29-Sep 4       Impact factor: 49.962

4.  ARPE-19, a human retinal pigment epithelial cell line with differentiated properties.

Authors:  K C Dunn; A E Aotaki-Keen; F R Putkey; L M Hjelmeland
Journal:  Exp Eye Res       Date:  1996-02       Impact factor: 3.467

5.  RB protein status and chemosensitivity in non-small cell lung cancers.

Authors:  Y Yamamoto; E Shimizu; N Masuda; M Takada; S Sone
Journal:  Oncol Rep       Date:  1998 Mar-Apr       Impact factor: 3.906

6.  Human retinal pigment epithelium cells as functional models for the RPE in vivo.

Authors:  Zsolt Ablonczy; Mohammad Dahrouj; Peter H Tang; Yueying Liu; Kumar Sambamurti; Alan D Marmorstein; Craig E Crosson
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-04       Impact factor: 4.799

Review 7.  Targeted drug delivery via the folate receptor.

Authors:  J Sudimack; R J Lee
Journal:  Adv Drug Deliv Rev       Date:  2000-03-30       Impact factor: 15.470

8.  The international incidence of childhood cancer.

Authors:  D M Parkin; C A Stiller; G J Draper; C A Bieber
Journal:  Int J Cancer       Date:  1988-10-15       Impact factor: 7.396

9.  Retinoblastoma--origin from a primitive neuroectodermal cell?

Authors:  A P Kyritsis; M Tsokos; T J Triche; G J Chader
Journal:  Nature       Date:  1984 Feb 2-8       Impact factor: 49.962

10.  Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery.

Authors:  Takahiro Hatanaka; Masayuki Haramura; You-Jun Fei; Seiji Miyauchi; Christy C Bridges; Preethi S Ganapathy; Sylvia B Smith; Vadivel Ganapathy; Malliga E Ganapathy
Journal:  J Pharmacol Exp Ther       Date:  2003-11-14       Impact factor: 4.030

View more
  14 in total

1.  Novel pentablock copolymer-based nanoparticulate systems for sustained protein delivery.

Authors:  Sulabh P Patel; Ravi Vaishya; Dhananjay Pal; Ashim K Mitra
Journal:  AAPS PharmSciTech       Date:  2014-10-16       Impact factor: 3.246

2.  [Targeted imaging ability of a biotinylated imaging probe Biotin-S-S-Rhodol for breast cancer cells in vitro].

Authors:  Bi-Juan Wu; Xing-Zi Zhou; Jing-Wen Sun; Cui-Wen Tan; Xin-Rong Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-01-20

3.  Molecular expression and functional activity of efflux and influx transporters in hypoxia induced retinal pigment epithelial cells.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; V K Chaithanya Ponnaluri; Dhananjay Pal; Mridul Mukherji; Ashim K Mitra
Journal:  Int J Pharm       Date:  2013-07-01       Impact factor: 5.875

4.  Lipopolysaccharide inhibits colonic biotin uptake via interference with membrane expression of its transporter: a role for a casein kinase 2-mediated pathway.

Authors:  Ram Lakhan; Hamid M Said
Journal:  Am J Physiol Cell Physiol       Date:  2017-01-04       Impact factor: 4.249

5.  Dual-Target Multifunctional Superparamagnetic Cationic Nanoliposomes for Multimodal Imaging-Guided Synergistic Photothermal/Photodynamic Therapy of Retinoblastoma.

Authors:  Wendi Zheng; Xing Li; Hongmi Zou; Yan Xu; Pan Li; Xiyuan Zhou; Mingxing Wu
Journal:  Int J Nanomedicine       Date:  2022-07-26

6.  Functional and molecular aspects of biotin uptake via SMVT in human corneal epithelial (HCEC) and retinal pigment epithelial (D407) cells.

Authors:  Aswani Dutt Vadlapudi; Ramya Krishna Vadlapatla; Dhananjay Pal; Ashim K Mitra
Journal:  AAPS J       Date:  2012-08-18       Impact factor: 4.009

7.  Expression profile and functional activity of peptide transporters in prostate cancer cells.

Authors:  Wanyi Tai; Zhijin Chen; Kun Cheng
Journal:  Mol Pharm       Date:  2012-09-21       Impact factor: 4.939

8.  Enhanced receptor-mediated endocytosis and cytotoxicity of a folic acid-desacetylvinblastine monohydrazide conjugate in a pemetrexed-resistant cell line lacking folate-specific facilitative carriers but with increased folate receptor expression.

Authors:  Rongbao Zhao; Ndeye Diop-Bove; I David Goldman
Journal:  Mol Pharmacol       Date:  2013-11-18       Impact factor: 4.436

9.  Tailor-made pentablock copolymer based formulation for sustained ocular delivery of protein therapeutics.

Authors:  Sulabh P Patel; Ravi Vaishya; Gyan Prakash Mishra; Viral Tamboli; Dhananjay Pal; Ashim K Mitra
Journal:  J Drug Deliv       Date:  2014-06-22

10.  Folate Decorated Nanomicelles Loaded with a Potent Curcumin Analogue for Targeting Retinoblastoma.

Authors:  Hashem Alsaab; Rami M Alzhrani; Prashant Kesharwani; Samaresh Sau; Sai Hs Boddu; Arun K Iyer
Journal:  Pharmaceutics       Date:  2017-04-18       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.